Korro Bio (KRRO) Price & Analysis

Compare

519 Followers

KRRO Stock Chart & Stats

$33.84

-$1.03(-2.68%)

At close: Jan 08 4:00 PM EST

$33.84

-$1.03(-2.68%)

Day’s Range― - ―

52-Week Range$10.29 - $75.00

Previous CloseN/A

Volume28.02K

Average Volume (3M)268.91K

Market Cap

$317.88M

Enterprise Value$64.56M

Total Cash (Recent Filing)$96.36M

Total Debt (Recent Filing)$44.63M

Price to Earnings (P/E)―

Beta3.00

Next Earnings

Nov 18, 2025

EPS Estimate

-2.59

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.74

Shares Outstanding9,390,903

10 Day Avg. Volume321,631

30 Day Avg. Volume268,914

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)2.12

Price to Sales (P/S)149.54

P/FCF Ratio-4.36

Enterprise Value/Market Cap0.20

Enterprise Value/Revenue10.28

Enterprise Value/Gross Profit15.31

Enterprise Value/Ebitda-0.68

Forecast

1Y Price Target

$119.00

Price Target Upside251.65% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsMore than 80% of planned healthy volunteers have been dosed in the KRRO-110 trial with no serious adverse events or dose-limiting toxicities observed.

Commercial OpportunityThe lead program KRRO-110 aims to treat AATD and presents a significant commercial opportunity due to high unmet need and lack of approved disease-modifying therapies.

Growth OpportunitiesA second development candidate is planned for nomination in a rare metabolic disorder, indicating potential future growth opportunities.

Bears Say

Financial OutlookThe price target has been lowered to $90 due to financial results and potential share dilution.

Market RisksPossible long-term dilution risk is a concern for Korro Bio, Inc.

Pipeline RisksRisks include delays in advancing pipeline candidates, failure to generate favorable clinical data, and possible dilution risk.

Korro Bio News

Korro Bio initiated with a Buy at Clear Street

Clear Street analyst Bill Maughan initiated coverage of Korro Bio (KRRO) with a Buy rating and $93 price...

10d ago

KRRO

Three new option listings and fifteen option delistings on October 21st

New option listings for October 21st include Defiance Daily Target 2X Long IONQ ETF (IONX), Korro Bio Inc...

20d ago

KRRO

PTRN

Korro Bio’s KRRO-110 Study: A Potential Game-Changer in Genetic Therapy

Korro Bio, Inc. (($KRRO)) announced an update on their ongoing clinical study. Study Overview: Korro Bio, Inc. is...

13d ago

KRRO

Korro Bio CFO Vineet Agarwal Resigns, Interim Appointed

Korro Bio ( ($KRRO) ) just unveiled an announcement. On October 7, 2025, Vineet Agarwal announced his resignation...

1M ago

KRRO

Korro Bio management to meet with Piper Sandler

Meeting to be held in New York on September 30 hosted by Piper Sandler. Published first on TheFly...

2M ago

KRRO

Korro Bio’s Promising RNA Editing Advances and Market Potential Highlighted by Buy Rating

Korro Bio, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kostas Biliouris from...

2M ago

KRRO

Korro Bio’s KRRO-110: Promising Safety, Efficacy, and Commercial Potential Drive Buy Rating

BMO Capital analyst Kostas Biliouris maintained a Buy rating on Korro Bio yesterday and set a price target...

3M ago

KRRO

Korro Bio price target lowered to $90 from $100 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Korro Bio (KRRO) to $90 from $100 and keeps a...

3M ago

KRRO

Korro Bio Advances RNA Editing Programs in Q2 2025

Korro Bio, Inc. ( ($KRRO) ) has released its Q2 earnings. Here is a breakdown of the information...

3M ago

KRRO

Korro Bio reports Q2 EPS ($2.74), consensus ($2.59)

Reports Q2 revenue $1.46M, consensus $406.9k. Ram Aiyar, Ph.D., CEO and President of Korro, said, “Throughout the second...

3M ago

KRRO

Buy Rating for Korro Bio Driven by Promising KRRO-110 and Orphan Drug Designation

Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on Korro Bio, retaining the price target of...

4M ago

KRRO

Korro Bio receives European Medicines Agency granted ODD for KRRO-110

Korro Bio (KRRO) announced that it has been granted orphan drug designation, ODD, by the European Medicines Agency,...

4M ago

KRRO

Korro Bio management to meet with Piper Sandler

Meeting to be held on July 14 hosted by Piper Sandler. Published first on TheFly – the ultimate...

4M ago

KRRO

Korro Bio Elects New Directors at Annual Meeting

Korro Bio ( ($KRRO) ) has provided an update. At the 2025 annual meeting held on June 11,...

5M ago

KRRO

KRRO FAQ

What was Korro Bio’s price range in the past 12 months?

Korro Bio lowest stock price was $10.29 and its highest was $75.00 in the past 12 months.

What is Korro Bio’s market cap?

Korro Bio’s market cap is $317.88M.

When is Korro Bio’s upcoming earnings report date?

Korro Bio’s upcoming earnings report date is Nov 18, 2025 which is in 8 days.

How were Korro Bio’s earnings last quarter?

Korro Bio released its earnings results on Aug 12, 2025. The company reported -$2.74 earnings per share for the quarter, missing the consensus estimate of -$2.565 by -$0.175.

Is Korro Bio overvalued?

According to Wall Street analysts Korro Bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Korro Bio pay dividends?

Korro Bio does not currently pay dividends.

What is Korro Bio’s EPS estimate?

Korro Bio’s EPS estimate is -2.59.

How many shares outstanding does Korro Bio have?

Korro Bio has 9,390,903 shares outstanding.

What happened to Korro Bio’s price movement after its last earnings report?

Korro Bio reported an EPS of -$2.74 in its last earnings report, missing expectations of -$2.565. Following the earnings report the stock price went up 6.246%.

Which hedge fund is a major shareholder of Korro Bio?

Currently, no hedge funds are holding shares in KRRO

Korro Bio Stock Smart Score

Neutral

Fundamentals

Return on Equity

-58.34%

Trailing 12-Months

Asset Growth

-27.71%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Korro Bio

Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.

Korro Bio (KRRO) Earnings & Revenues

Historic Earnings Reports

KRRO Stock 12 Month Forecast

Average Price Target

$119.00

▲(251.65% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","52":"$52","95":"$95","138":"$138","181":"$181"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":180,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$180.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":119,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$119.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$85.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,52,95,138,181],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.905,54.37384615384616,64.84269230769232,75.31153846153846,85.78038461538462,96.24923076923078,106.71807692307692,117.18692307692308,127.65576923076924,138.1246153846154,148.59346153846155,159.06230769230768,169.53115384615387,{"y":180,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.905,49.681538461538466,55.45807692307692,61.23461538461538,67.01115384615385,72.78769230769231,78.56423076923076,84.34076923076923,90.11730769230769,95.89384615384616,101.67038461538462,107.44692307692307,113.22346153846154,{"y":119,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.905,47.066153846153846,50.22730769230769,53.38846153846154,56.549615384615386,59.71076923076923,62.87192307692308,66.03307692307692,69.19423076923077,72.35538461538462,75.51653846153846,78.67769230769231,81.83884615384616,{"y":85,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":47.72,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.16,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.5,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.07,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.07,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.95,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.395,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.8,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.77,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.85,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.205,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.905,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >